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Rapid expansion of Treg cells protects from
collateral colitis following a viral trigger
Michelle Schorer1, Katharina Lambert1,7, Nikolas Rakebrandt1, Felix Rost1, Kung-Chi Kao1,
Alexander Yermanos2,3, Roman Spörri 2, Josua Oderbolz2, Miro E. Raeber 4, Christian W. Keller 1,8,
Jan D. Lünemann 1,8, Gerhard Rogler5, Onur Boyman 4,6, Annette Oxenius 2 & Nicole Joller 1✉
Foxp3+ regulatory T (Treg) cells are essential for maintaining peripheral tolerance and
preventing autoimmunity. While genetic factors may predispose for autoimmunity, additional
environmental triggers, such as viral infections, are usually required to initiate the onset of
disease. Here, we show that viral infection with LCMV results in type I IFN-dependent Treg
cell loss that is rapidly compensated by the conversion and expansion of Vβ5+ conventional
T cells into iTreg cells. Using Vβ5-deﬁcient mice, we show that these Vβ5+ iTreg cells are
dispensable for limiting anti-viral immunity. Rather, the delayed replenishment of Treg cells in
Vβ5-deﬁcient mice compromises suppression of microbiota-dependent activation of CD8+
T cells, resulting in colitis. Importantly, recovery from clinical symptoms in IBD patients is
marked by expansion of the corresponding Vβ2+ Treg population in humans. Collectively, we
provide a link between a viral trigger and an impaired Treg cell compartment resulting in the
initiation of immune pathology.
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Regulatory T cells (Treg cells) expressing the transcriptionfactor FOXP3 represent a unique population of CD4+ Thelper cells that are essential for maintaining immune
homeostasis. Treg cells ensure peripheral tolerance by controlling
autoreactive T cells that have escaped thymic selection and their loss
results in overt autoimmune disease as seen in patients with
immunodysregulation polyendocrinopathy enteropathy X-linked
(IPEX) syndrome, which lack functional Treg cells due to a muta-
tion in FOXP31. Moreover, lack of Treg-mediated immune control is
a key feature of numerous autoimmune diseases and their models2,3.
Speciﬁcally, several autoimmune conditions, including rheumatoid
arthritis (RA), systemic lupus erythematosus (SLE), and inﬂamma-
tory bowel disease (IBD), are characterized by a relative loss of Treg
cells or their functional impairment4–9. However, what triggers this
loss or functional impairment is still unclear.
Viral infections have been suggested as triggers of auto-
immunity and a number of autoimmune diseases show a strong
linkage to certain viral infections8,10,11. Furthermore, viral gas-
trointestinal infections have been associated with a higher like-
lihood to develop IBD later in life12. Viral infection triggers
robust anti-viral immunity that is often dominated by a strong
interferon (IFN) response to mediate viral control. However,
particularly type I IFNs might play an ambivalent role in this
context. On the one hand they represent a powerful immune
defense mechanism against the viral infection13,14, on the other
hand they play an important role in exacerbating autoimmune
diseases, such as SLE or RA15–17. Interestingly, long-term IFNα
therapy as used in cancer and hepatitis patients can precipitate
SLE and systemic sclerosis18–20. Type I IFNs support a vast array
of protective host defense mechanisms including the restriction of
viral replication14, NK cell cytotoxicity21, and survival of cyto-
toxic T cells22. In addition, recent studies revealed that type I IFN
receptor (IFNAR) engagement also impacts on Treg cell activa-
tion and proliferation under inﬂammatory conditions23,24.
However, how viral infections and the concomitant type I IFN
response might affect the ability of Treg cells to maintain per-
ipheral tolerance has not been addressed.
Using lymphocytic choriomeningitis virus (LCMV) infection as
a model, we investigated how the Treg cell compartment is affected
during viral infections that induce a strong type I IFN response.
Our results show that the transient loss of Treg cells, mediated by
type I IFNs, is rapidly compensated by induced Treg (iTreg) cells.
This Treg population is dominated by a single β chain TCR, Vβ5.
Infection of Vβ5-deﬁcient mice revealed that absence of Vβ5+ Treg
cells has no direct effect on anti-viral immunity. In contrast, Vβ5+
Treg cells are essential for restraining an underlying colitogenic
CD8+ T cell response. This colitis is triggered by microbial anti-
gens released due to increased intestinal permeability resulting
from the viral infection. We found that Vβ5+ T cells harbour a
higher potential to convert into Tregs and display enhanced
proliferation as they receive an intrinsically elevated TCR signal.
This also manifests in an overrepresentation of Vβ5+ T cells
within the Treg pool at steady-state. We also identify Vβ2+
T cells as the corresponding population in humans that is over-
represented in colitis patients with inactive disaese. In summary,
we demonstrate that the virus-induced type I IFN response
transiently compromises the Treg compartment and that a rapid
compensation through conversion of Vβ5+ T cells into Treg cells
is necessary to prevent autoimmune inﬂammation.
Results
iTregs compensate transient Treg loss upon viral infection. To
determine how viral infections and the ensuing immune
response affect the Treg compartment, we used LCMV as a
model for a viral infection eliciting a potent type I IFN
response25. We used LCMV strain WE to induce acute and
LCMV strain clone 13 to induce chronic infection26,27. In line
with previous studies23,24, we observed a pronounced loss in
Treg cells at the peak of immune response upon LCMV infection
(day 5–7; Fig. 1a), coinciding with marked weight loss (Supple-
mentary Fig. 1a)28,29. However, this loss in Treg cells was only
transient as the Treg niche was readily replenished upon
recovery, predominantly with CXCR3+Nrp1– iTreg cells (Fig. 1b,
Supplementary Fig. 1b, c). While both acute and chronic LCMV
infection resulted in an expansion of CXCR3+ iTreg cells, it was
most pronounced upon chronic LCMV infection, where per-
ipherally induced CXCR3+Nrp1− iTreg cells accounted for over
half of the Treg population (Fig. 1c).
Depending on the strain, LCMV can cause acute or chronic
infections with varying intensities of anti-viral type I IFN
responses26,27. To assess the Treg composition in these different
scenarios, we infected mice with a range of LCMV strains that
result in acute (Armstrong, WE) or chronic (Clone 13, Docile)
infection. Analyzing the TCR composition by ﬂow cytometry, we
noticed that all LCMV strains selectively enriched for Vβ5.1,5.2+
Treg cells, although the effect was most pronounced in chronic
infections (Fig. 1d, Supplementary Fig. 1d). Comprehensive
analysis of TCR usage from RNA-Seq data of Foxp3+ and
Foxp3− T cells during acute LCMV infection30 further conﬁrmed
that the Vβ5.2-encoding Trbv12-1 was the only transcript
speciﬁcally enriched within the Treg population upon LCMV
infection, while no changes were observed in the effector T cell
population (Supplementary Fig. 1e). The Vβ5+ Treg cells
replenishing the regulatory compartment after LCMV infection
were predominantly negative for Nrp1, a marker of thymically
derived Treg cells31,32. Vβ8+ Treg cells, which showed no
increase, served as controls (Fig. 1e). As there has recently been
some debate about the ﬁdelity of Nrp1 as a marker for nTreg
cells33,34, we next performed a proof-of-principle experiment to
determine whether bona ﬁde induced Treg cells would be
dominated by Vβ5+ Treg cells. To this end, we adoptively
transferred congenically marked CD4+Foxp3− T cells or total
CD4+ T cells into OT-II mice, in which all T cells express an
ovalbumin-speciﬁc TCR and thus cannot mount an endogenous
T cell response against LCMV. Upon LCMV (but not Vaccinia
virus) infection we observed a robust induction of Vβ5+ Treg cells
within the transferred cells (Fig. 1f). Importantly, mice that had
received CD4+Foxp3− T cells and thus only harboured iTreg cells
showed an even stronger dominance of Vβ5+ Treg cells than mice
that received total CD4+ T cells and thus harboured a mixture of
nTreg and iTreg cells (Fig. 1f), conﬁrming that the Vβ5+ Treg
pool upon LCMV infection is dominated by iTreg cells.
Next, we wanted to determine whether the relative expansion
of Vβ5+ iTreg cells was dependent on the transient reduction of
Treg cells caused by the type I IFN response elicited upon LCMV
infection23,24. Indeed, Vβ5+ Treg cell accumulation was not
observed upon infection with other acute (Vaccinia) or chronic
(MCMV) viral infections or UV-inactivated LCMV that induce a
less potent type I IFN response (Supplementary Fig. 2a–c)35,36.
Furthermore, we could observe a highly signiﬁcant positive
correlation between the peak serum type I IFN levels elicited by
different viral infections and the frequencies of Vβ5+ iTreg cells
(Fig. 1g and Supplementary Fig. 2d). We also found strongly
reduced Vβ5+ iTreg cell frequencies and numbers in mice lacking
the type I IFN receptor (IFNAR, Ifnar1−/− mice; Fig. 1h).
Comparing the frequency of Vβ5+ iTregs in mesenteric LNs
(mLNs) and colons of WT and Ifnar1−/− mice, we found a
comparable reduction of Vβ5+ iTreg frequencies in the colon
(Supplementary Fig. 2e).
Next, we set out to determine whether type I IFN directly
promoted the induction of Vβ5+ iTreg cells or whether this was
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Fig. 1 Induced Treg cells compensate for Treg cell loss caused by type I interferons. a–cWTmice were infected with 200 f.f.u. LCMVWE (acute), 106 f.f.u.
LCMV clone 13 (chronic), or were left naive. a Total numbers of CD4+Foxp3+ splenic Treg cells were determined by ﬂow cytometry throughout the course of
infection (n= 3–11). Frequencies (b) and total numbers (c) of CD4+Foxp3+CXCR3+Nrp1− iTreg and CD4+Foxp3+CXCR3+Nrp1+ nTreg cells were determined
in naive and LCMV-infected mice on day 14 post infection (n= 9–12). d WT mice were infected with LCMV WE (200 f.f.u.), Armstrong (106 f.f.u.), clone 13
(106 f.f.u.), or Docile (106 f.f.u.) and frequencies of CD4+Foxp3+ Treg or CD4+Foxp3− conventional T cells expressing the indicated Vβ chains were determined
by ﬂow cytometry (day 10; n= 3–10). e Frequencies of TCR Vβ5+ and Vβ8+ cells among CD4+Foxp3+CXCR3+Nrp1− iTreg and CD4+Foxp3+CXCR3+Nrp1+
nTreg cells were determined by ﬂow cytometry as in c (day 14; n= 11–18). f Flow sorted CD45.1+CD4+Foxp3− T cells and CD90.1+CD4+ T cells were
adoptively co-transferred into CD45.2+ OT-II mice. Reconsituted mice were infected the next day with LCMV WE (200 f.f.u., acute), clone 13 (106 f.f.u.,
chronic), or Vaccinia virus (106 f.f.u.) or were left naive. Vβ5+ frequencies among donor CD4+Foxp3+ were determined on day 10 (n= 3). g WT mice were
infected with Vaccinia virus (106 f.f.u.), Vaccinia Virus + poly IC (2 × 50 μg/mouse, day 0 and 2), LCMVWE (200 f.f.u.), LCMVWE+ poly IC, or LCMV clone
13 (106 f.f.u.) and type I IFN levels in the blood 24 h after infection were correlated with frequencies of Vβ5+ CD4+Foxp3+CXCR3+Nrp1− iTreg cells on day 10
post infection (n= 2 values per condition, pooled from 2–3 mice). h WT, Ifnar1−/−, or Ifnar1−/− mice that had received 106 Thy1.1+ CD4+ T cells i.v. one day
before were chronically infected with 106 f.f.u. LCMV clone 13 and frequencies and total numbers of Vβ5+ CD4+Foxp3+ Treg or Vβ5+ CD4+Foxp3−
conventional T cells were determined by ﬂow cytometry (day 10; n= 4–13). In summary plots, data are shown as mean ± SD. For statistics, Mann–Whitney U
(c, e) or one-way ANOVA (d, f, h) was used.
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an indirect effect caused by type I IFN-dependent reduction in
Treg cells upon LCMV infection23,24 (Supplementary Fig. 2f). We
found that type I IFN had no effect on the conversion of
CD4+Foxp3− T cells into iTreg cells in vitro (Supplementary
Fig. 2g). To conﬁrm this in vivo, we transferred congenically
marked WT CD4+ T cells into Ifnar1−/− mice before infecting
them with LCMV. In this setting, type I IFN is produced but
cannot be sensed by endogenous T cells, preventing Treg cell loss.
In contrast, the transferred cells can receive a type I IFN signal and,
if this directly promotes Vβ5+ iTreg induction, we expect to see
increased Vβ5+ iTreg cells. However, this was not the case as we
observed very low frequencies of Vβ5+ iTreg cells in this setting
(Fig. 1h), conﬁrming that type I IFN does not directly promote
Vβ5+ iTreg conversion or expansion. Taken together, we found
that LCMV infection results in type I IFN-dependent induction of
a dominant Vβ5+ iTreg population. Importantly, type I IFN does
not directly induce Vβ5+ iTreg cells but compromises the Treg
niche and thereby allows for the selective enrichment of this
population. We have thus identiﬁed a dominant iTreg population
that drives Treg cell replenishment under inﬂammatory conditions
as those induced by type I IFN-dominated viral infections.
Vβ5+ Tregs are not required to control anti-viral immunity.
Given the dominace of the Vβ5+ Treg population upon LCMV
infection, we next investigated its suppressive capacity and impact
on the anti-viral effector response. CXCR3+Vβ5+ iTreg cells
expressed normal or even slightly elevated levels of the Treg
signature genes Foxp3 and CTLA-4 and the co-inhibitory
receptor signature of Th1-suppressive Treg cells (Lag-3, Tim3,
and CD85k30) when compared to total CXCR3+ Treg cells or
Vβ5+ nTreg cells, respectively (Fig. 2a, Supplementary Fig. 3a–d).
While PD-1 expression was decreased on CXCR3+Vβ5+ iTreg
cells upon acute LCMV infection, levels in chronically infected
mice were comparable and expression of TIGIT, which marks a
highly suppressive Treg subset37, was even increased (Fig. 2b, c).
Furthermore, CXCR3+Vβ5+ iTreg cells strongly expressed the
ectonucleotidase CD39 and the inhibitory cytokine IL-10 (Fig. 2b,
c and Supplementary Fig. 3e). Furthermore, the suppressive
capacity of CXCR3+Vβ5+ iTreg cells was comparable to that of
other Treg subsets when tested in an in vitro suppression assay
(Fig. 2d). Infection-induced Vβ5+ iTreg cells are thus fully
functional and have the suppressive capacity to control effector
T cells.
To elucidate the functional relevance of Vβ5+ Treg cells during
LCMV infection, we next investigated the LCMV-speciﬁc
immune response in mice selectively lacking Vβ5+CD4+
T cells. To this end, Tcrb−/−Tcrd−/− mice that lack all T cells
were reconstituted with WT CD8+ T cells together with either
total CD4+ T cells or Vβ5−CD4+ T cells (Fig. 2e). Surprisingly,
the LCMV-speciﬁc immune response in animals reconstituted
with Vβ5−CD4+ T cells and thus lacking Vβ5+ Treg cells was
largely comparable to that observed in control mice. Stimulation
with the immunodominant epitopes resulted in comparable IFN-
γ production by CD4+ T cells and only slightly elevated
frequencies of IFN-γ+ CD8+ T cells in mice lacking Vβ5+
CD4+ T cells (Fig. 2f). Furthermore, viral control was unaltered
as viral titers in liver, kidney and spleen were comparable between
the two groups (Fig. 2g). This is in contrast to mice depleted of
Treg cells, which fully clear the virus (Fig. 2g). Thus, despite the
fact that about half the Foxp3+ Treg cells present upon LCMV
infection are Vβ5+, they do not play an essential role in
controlling the anti-viral immune response.
Vβ5+ Tregs protect from virus-induced colitis. Although
LCMV-infected animals mounted a comparable anti-viral effector
response in the absence of Vβ5+ T cells (Fig. 2e–g), we noticed
that they developed severe intestinal pathology that was mostly
localized to the lower gastrointestinal tract (‘ΔVβ5’, Fig. 3a). To
determine whether this was due to a loss in Vβ5+ Treg cells or
Vβ5+ effector T cells that are also lacking in this setting, we
reconstituted Tcrb−/−Tcrd−/− mice with WT CD8+ T cells
together with Vβ5−CD4+ WT T cells plus Vβ5+CD4+ T cells
from DEREG mice and selectively depleted Vβ5+ Treg but not
effector T cells by diphtheria toxin administration. As in the Vβ5-
deﬁcient setting, we observed intestinal pathology upon LCMV
infection (“ΔVβ5+DEREG Vβ5+”, Fig. 3a), demonstrating that
the Vβ5+ Treg compartment in LCMV-infected mice safeguards
the host from a colitogenic response at the intestinal mucosal
barrier. The functional importance of the Vβ5+ Treg cells in this
regard was further strengthened by the fact that the colitogenic
response in ΔVβ5 mice could be rescued by adoptive transfer of
Vβ5+Foxp3+ Treg cells isolated from LCMV-infected Foxp3−
GFP.KI mice (“ΔVβ5+Vβ5+ Treg AT”, Fig. 3a). Importantly,
this protective effect was limited to Vβ5+ Treg cells as Vβ8+
Foxp3+ Treg cells were not capable of rescuing ΔVβ5 mice from
colitis (“ΔVβ5+Vβ8+ Treg AT”, Fig. 3a). Interestingly, mice in
which Vβ5+ T cells lack the type I IFN receptor also did not
develop intestinal pathology (“ΔVβ5+ IFNAR−/− Vβ5+”,
Fig. 3a), conﬁrming our previous ﬁnding that type I IFN does not
directly act on Vβ5+ T cells but rather plays an indirect role by
compromising the Treg niche (Fig. 1h).
Next, we set out to identify the colitogenic effectors that are
regulated by Vβ5+ Treg cells upon LCMV infection. Looking at
the mLN, we observed higher frequencies of IFN-γ+ CD8+ but
not CD4+ T cells in ΔVβ5 mice upon PMA/ionomycin
stimulation (Fig. 3b). To dermine whether CD8+ T cells might
be driving the intestinal inﬂammation observed in ΔVβ5 mice, we
next reconstituted Tcrb−/−Tcrd−/− mice with Vβ5−CD4+ WT
T cells without any CD8+ T cells and infected them with LCMV.
In the absence of CD8+ T cells we did not observe any
inﬂammation (“ΔVβ5, no CD8+ T cells”, Fig. 3a), conﬁrming that
CD8+ T cells drive the intestinal inﬂammation in ΔVβ5 mice.
We hypothesized that the enhanced CD8+ T cell response
observed in the mLN (Fig. 3b) might occur in response to a
barrier dysfunction caused by the infection-induced inﬂamma-
tory response. We thus used an in vivo FITC-dextran feeding
assay38 to test the intestinal permeability upon LCMV infection
and indeed found the barrier integrity at the gut mucosal
interface to be substantially impaired in both WT and ΔVβ5
animals (Fig. 3c). This increased permeability was of functional
relevance for colitis development as colitis in ΔVβ5 mice could be
prevented by broad-spectrum antibiotic therapy that removed
their commensal ﬂora (“ΔVβ5+ABX”, Fig. 3a). We next tested
the ability of CD4+ and CD8+ effector T cells to respond to gut-
derived macromolecular antigens and microbe-associated mole-
cular patterns (MAMP) and found that CD8+ but not CD4+
T cells responded to puriﬁed gut content with pro-inﬂammatory
cytokine secretion (Fig. 3d and Supplementary Fig. 4). Taken
together, these data reveal that increased intestinal permeability
associated with viral infection triggers a colitogenic immune
response that is kept in check by Vβ5+ Treg cells.
LCMV infection induces a polyclonal Vβ5+ iTreg response.
Next we wanted to address the underlying mechanism driving the
expansion of CXCR3+Vβ5+ Treg cells during LCMV challenge.
First, we analyzed the clonal diversity of the Vβ5+ T cell pool by
looking at CDR3 sequence diversity in Trbv12-1(Vβ5.2)-using
CD4+ T cells at the peak of disease (day 14). CXCR3+ Treg cells
from LCMV-infected animals displayed a substantial clonal over-
lap between different mice that was not observed in naive Treg or
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effector CD4+ T cells (Fig. 4a, left). Importantly, this high number
of public clones was a unique feature of Vβ5+CXCR3+ Treg cells
as Trbv13-2(Vβ8.1)-using Treg cells only showed a slight increase
in clonal overlap upon LCMV infection (Fig. 4a, right). Never-
theless, Trbv12-1-using CXCR3+ Treg cells also harboured by
far the highest number of unique clones within the entire TCR
repertoire, even when compared to Foxp3−CD4+ effector T cells
(Fig. 4b). To further elucidate what drives the highly polyclonal
expansion of CXCR3+Vβ5+ iTreg cells, we next focused on the
mechanisms that drive their MHC class II-dependent priming.
Class II ligands are mainly derived from exogenous antigens and
processed via lysosomal degradation39. In addition, around 20% of
the epitopes present on MHC II molecules originate from intra-
cellular sources40, which can gain access to MHC class II
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loading compartments through autophagy protein-dependent
antigen processing41. To investigate whether endogenous antigen
might play a role in priming of CXCR3+Vβ5+ iTreg cells, we
analyzed the LCMV-induced changes in the Treg compartment of
Atg5ﬂ/ﬂxItgaxCre/− mice, in which classical CD11c+ dendritic cells
(DCs) lack Atg5, an essential protein of the autophagy machin-
ery42. LCMV infection in Atg5ﬂ/ﬂxItgaxCre/− mice resulted in
strongly enlarged spleens (Fig. 4c) and elevated numbers of CD4+
T cells and Foxp3+ Treg cells (Fig. 4d and Supplementary Fig. 5a).
However, frequencies of virus-speciﬁc CD4+ and CD8+ effector
T cells and viral clearance were comparable to those of control
mice (Fig. 4e and Supplementary Fig. 5b). Interestingly, we
observed a stronger induction of Vβ5+ iTreg cells in acutely
infected Atg5ﬂ/ﬂxItgaxCre/− mice (Fig. 4f), suggesting that exo-
genous antigens might be the primary driver of Vβ5+ iTreg
expansion. However, we did not observe an increase in Vβ5+ iTreg
priming upon chronic infection (Fig. 4c–f), possibly because the
high amount of antigens present in this setting already allows for
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maximal iTreg accumulation. Also, no changes in Vβ5+ iTreg
induction were evident when the microbiota was depleted by
antibiotic treatment (Supplementary Fig. 5c–e), suggesting that,
unlike the colitigenic CD8+ T cell response, induction of Vβ5+
iTreg cells is not driven by microbial antigens. In summary, this
data suggests that mostly exogenous antigens drive the expansion
of a polyclonal Vβ5+ iTreg pool during LCMV infection.
Vβ5+ T cells preferentially convert into Treg cells. We next
wanted to determine why Vβ5+ but not other CD4+ effector
T cells predominantly converted into iTregs to compensate for
the early type I IFN-dependent Treg reduction. When we
enumerated total Treg cells in our model of TCR-deﬁned
reconstitution (Fig. 2e), we observed that mice lacking Vβ5+
CD4+ T cells still showed a pronounced loss of Treg cells 10 days
after LCMV infection while controls had already recovered their
Treg cell numbers (Fig. 5a and Supplementary Fig. 6a). Never-
theless, by day 17 Treg cell numbers in ΔVβ5 mice were
comparable to those in controls, as Treg cells carrying other Vβ
chains had compensated (Fig. 5a, b, Supplementary Fig. 6a).
We further observed that Vβ5+ Treg cells showed an almost
2-fold higher proliferation rate than other Treg populations as
determined by BrdU incorporation (Fig. 5c), suggesting that
Vβ5+CD4+ T cells can more rapidly expand to replenish the Treg
niche. To investigate the molecular mechanisms behind their
augmented capacity to ﬁll the Treg niche, we ﬁrst analyzed the
strength of TCR stimulation in Vβ5+CXCR3+Nrp1− iTreg and
conventional CD4+Foxp3− T cells. Nur77 (encoded by Nr4a1) is
an early indicator of TCR signaling in lymphocytes43,44 and we
used Nr4a1-GFP reporter mice to analyze TCR signaling in Vβ5+
and control T cells upon LCMV infection. We observed an ele-
vated level of TCR stimulation in Vβ5+ iTreg cells that
was sustained throughout the course of infection (Fig. 5d, Sup-
plementary Fig. 6b). Of note, already at steady-state both Vβ5+
iTreg and Vβ5+CD4+Foxp3− conventional T cells showed a
higher signal than T cells carrying other TCR β chains (Fig. 5d).
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The intrinsically higher TCR signal in Vβ5+CD4+ T cells was
also reﬂected in elevated CD5 levels in these cells (Fig. 5e), which
are set during positive selection and correlate with the strength of
the TCR signal received during thymic development45,46.
We next tested whether Vβ5+ T cells also displayed a higher
propensity to convert into Foxp3+ iTreg cells. Both Vβ5+ and
Vβ5− T cells converted equally well in response to optimal
stimulation with TGF-β and IL-2 in vitro (Fig. 5f, left). However,
under suboptimal conditions with limiting amounts of IL-2 and
TGF-β, Vβ5+ T cells showed superior ability to convert into iTreg
cells (Fig. 5f, right). In line with our earlier ﬁndings, we also
observed a higher iTreg cell conversion rate when naive Foxp3−
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T cells were co-cultured with Atg5-deﬁcient CD11c+MHC II+
DCs isolated from LCMV-infected mice than with DCs from WT
mice (Fig. 5g), further supporting the notion that an exogenous
antigen is driving conversion of Vβ5+Foxp3− T cells into iTreg
cells. Strikingly, a substantial over-representation of Vβ5.2+ cells
within the Treg compared to the conventional T cell compart-
ment was already apparent at steady-state (Fig. 5h), supporting
the notion that Vβ5+ T cells preferentially convert into Treg cells
in vivo even in the absence of LCMV infection. Importantly,
when analyzing human T cells, we also found a speciﬁc over-
representation of a single Vβ chain, Vβ2 (TCRBV20-1), within the
Treg compartment (Fig. 5i). Like Vβ5+ Treg cells in mice, the
human Vβ2+ Treg population was highly polyclonal (Supple-
mentary Fig. 7). More importantly, Vβ2+ Treg cells, but not
T cells carrying other abundant Vβ chains, were speciﬁcally
expanded in IBD patients with inactive disease (Fig. 5j, k),
suggesting that recovery from clinical symptoms is marked by
high frequencies of Vβ2+ Treg cells. Taken together, these
ﬁndings show that effector T cells carrying speciﬁc TCR β chains
harbour an intrinsically higher potential to convert into Treg cells
allowing for the rapid replenishment of the Treg niche if it is
compromised by a virus-induced type I IFN response upon
infection (Fig. 6).
Discussion
In this study, we uncovered an essential role for iTreg cells
expressing speciﬁc Vβ chains in preventing autoimmunity upon
viral triggers. LCMV infection induces a type I IFN-dependent
loss of Treg cells that is rapidly compensated by the conversion of
high-afﬁnity Vβ5+ conventional T cells into iTreg cells. While
these Vβ5+ iTreg cells do not play a role in limiting the anti-viral
immune response, they are essential for suppression of colito-
genic CD8+ effector T cells at the gut barrier site. In humans, this
role is fulﬁlled by Vβ2+ Treg cells, which are speciﬁcally
expanded in IBD patients with inactive disease.
Treg cells are essential for the peripheral control of autoreactive
T cells as their loss results in autoimmunity47. Predisposing
genetic factors contribute to the manifestation of such auto-
immune conditions but in most cases additional environmental
triggers, such as viral infections, are required to initiate the onset
of disease8,48. However, the underlying mechanisms triggered by
the infectious challenge are still largely unclear. In this study, we
reveal that the anti-viral type I IFN response strongly compro-
mises the Treg compartment. This allows for the primimg of
colitogenic CD8+ T cells at the gut barrier site, resulting in
microbiota-dependent activation of CD8+ T cells and colitis. In
line with these results, Norovirus infection has been associated
with exacerbations and ﬂares of IBD49,50. Our data would suggest
that these ﬂares are the result of a transient reduction in Treg cells
that is compensated by the expansion and conversion of Vβ2+
T cells into Treg cells as observed in the IBD pateints with
inactive disease.
We further show that a rapid replenishment of the Treg pool
through enhanced conversion and expansion of a speciﬁc CD4+
T cell population into Foxp3+ iTreg cells is necessary to prevent
the onset of pathologic T cell responses. Using LCMV infection as
a model, we establish that non-microbiota speciﬁc Vβ5+ T cells
are selected based on an intrinsically high TCR signal and their
superior ability to convert into iTreg cells, enabling them to
rapidly replenish the Treg niche upon LCMV infection. The
highly polyclonal nature of the Vβ5+ iTreg response might sug-
gest that a global stimulus is involved. Indeed, earlier reports have
shown that LCMV infection results in the reactivation of endo-
genous mouse mammary tumor virus (MMTV)-encoded super-
antigens that can expand Vβ5+CD4+ nTreg cells51. Furthermore,
the fact that CXCR3+Vβ5+ Treg cells harbour a relatively high
number of public clones is consistent with superantigen-mediated
activation52. As such, it is likely that the polyclonal conversion
and expansion of Vβ5+CD4+ T cells into iTreg cells is in part
driven by these superantigens.
Like Vβ5+ T cells in mice, we found human T cells carrying the
Vβ2 chain to be highly overrepresented within the Treg pool
when compared to effector T cells, suggesting that they harbour
the same abilty as mouse Vβ5+ T cells to rapidly replenish a
compromised Treg niche. Indeed, Vβ2 was recently reported to
be overrepresented in the colon of patients with ulcerative colitis
or Crohn’s disease53. This is in line with our observation that IBD
patients with inactive disease have a higher proportion of Vβ2+
Treg cells that likely expanded to restore a compromised Treg
compartment.
High levels of type I IFN present during anti-viral responses
compromise the regulatory compartment23,24, but this can be
compensated by the rapid induction and expansion of iTreg cells.
However, if this process is impaired, such as in Vβ5-deﬁcient
mice as shown in this study, the compromised Treg compartment
is no longer able to limit autoreactive immune responses. Pro-
longed exposure to type I IFN, such as in IFN therapy or in
patients with type I interferonopathies that are characterized by
the constitutive production of type I IFNs, likely also impairs or
even prevents Treg cell replenishment, which then manifests in
inﬂammatory responses directed at self15,54. The fact that type I
Fig. 5 CD4+Vβ5+ T cells readily convert into iTreg cells. Tcrb−/−Tcrd−/− mice reconstituted with total or ΔVβ5 CD4+ T cells were infected with LCMV
clone 13 or left naïve, and analyzed 10 or 17 days after infection. Total splenic Treg counts (a) and their expression of CXCR3 and Nrp1 (b) was determined
by ﬂow cytometry (n= 4). c BrdU incorporation in splenic Treg cell populations 10 days post infection (n= 3−7). d Nr4a1-GFP mice were infected with
LCMV WE and frequencies of Nr4a1-GFP+ cells carrying the indicated TCR Vβ chain among CD4+Foxp3+CXCR3+Nrp1− iTreg (left) and CD4+Foxp3−
conventional T cells (right) were determined by ﬂow cytometry (n= 3–6). e CD5 expression in naïve thymic and splenic CD4+Foxp3− conventional T cells
and splenic CD4+Foxp3+ Treg cells was determined by ﬂow cytometry (n= 3). f Sorted CD4+CD25− T cells from naïve WT mice were co-cultured with
CD11c+MHCII+ cells (1:1) with titrated amounts of anti-CD3 (1:3 dilution steps) and 0.3 or 3 ng/ml TGF-β plus 2 or 20 U/ml IL-2 (low and high,
respectively). Foxp3+ frequencies among CD4+ T cells carrying the indicated TCR Vβ chain were determined by ﬂow cytometry (n= 3). g As in f under
low IL-2/TGF-β conditions with CD11c+MHCII+ cells isolated from LCMV-infected Atg5ﬂ/ﬂxItgaxCre/WT (KO) or Atg5ﬂ/f (WT) mice. Frequencies of
CD4+Foxp3+ Treg cells among CD4+Vβ5+ T cells (n= 3). h Transcriptional analysis of Trbv gene segments shown as relative expression against
expression in CD4+Foxp3+ Treg cells. i Analysis of TCR Vβ usage in healthy donor human Treg cells displayed as in h and determined by RNA-Sequencing
(bottom) and ﬂow cytometric spectratyping (top), (n= 6). j, k Expression of Vβ2, Vβ5.1, and Vβ17 TCR chains among CD4+CD127−CD25hi Treg and
CD4+CD127varCD25var effector T cells from healthy human donors (n= 5) or IBD patients with inactive (n= 8) or active (n= 5) disease was determined
by ﬂow cytometry. Data are presented as relative expression vs. expression in Treg cells (j) and as frequencies within Treg cells (k). Data are shown as
mean ± SD; summary graphs display pooled data of 2–3 independent experiments. For statistics, Mann–Whitney U (a, c, e, k) or one-way ANOVA (d, f, g)
was used.
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IFNs play a role in induction or exacerbation of e.g. SLE or RA19
and that IFN blocking strategies have shown promising results in
SLE patients in clinical trials further supports this hypothesis55.
Based on our results, we propose that a “division of labour” exists
between nTreg cells and Treg cells induced in the periphery.
Thymus-derived nTregs play a fundamental role in maintaining
self-tolerance and immune homeostasis under steady-state con-
ditions. However, upon an infectious challenge, the inﬂammatory
anti-pathogen response results in an initial depletion of IFN-
sensitive nTregs to allow for the initiation of a potent adaptive
immune response and pathogen clearance. However, this
impairment in immune control has to be transient in its nature to
ensure that activation of autoreactive cells in the periphery is
prevented. This requires a rapid replenishment of the Treg pool,
which can be achieved through expansion and conversion of
high-afﬁnity conventional T cells into iTreg cells. If this response
is compromised or other predisposing factors exist, the infection-
triggered transient reduction in Treg cells might serve as an
environmental trigger for autoimmunity.
Overall, our results support the concept that the Treg com-
partment as a whole is able to adapt to inﬂammatory insults that
may compromise peripheral tolerance. We show that virus-
induced type I IFN responses transiently impair the Treg cell
compartment, but that this is rapidly replenished by iTreg cells
converted from a high-afﬁnity CD4+ T cell pool to prevent
inﬂammatory disorders and overt autoimmunity.
Methods
Animals and infections. Animal experiments were reviewed and approved by
the cantonal veterinary ofﬁce of Zurich (permit numbers ZH100/2014, ZH168/
2015, ZH114/2017, ZH119/2017, and ZH179/2017) and were performed in
accordance with Swiss legislation. All mice were bred and housed at the ETH
Phenomics Center Zurich, Switzerland (C57BL/6-Tg(Nr4a1-EGFP/cre)820Khog/J
mice) and the Laboratory Animal Sciences Center (LASC) Zurich, Switzerland
(all other strains). C57BL/6Rj (WT) mice were purchased from Janvier Labs.
Foxp3-GFP.KI reporter mice56, B6.Cg-Tg(TcraTcrb)425Cbn/J (OT-II; JAX
00419457) mice, B6.Cg-Gpi1aThy1aIgha/J mice (Thy1.1; JAX 00131758),
Ifnar1tm1Agt mice (MMRC JAX 3204559), Tcrbtm1MomTcrdtm1Mom mice (JAX
00212260), and C57BL/6-Tg(Nr4a1-EGFP/cre)820Khog/J mice (JAX 01661743)
were described earlier. B6.SJL-PtprcaPepcb/BoyJ (Ly5.1; JAX 002014) and
Foxp3-GFP.KI mice were crossed to generate Foxp3-GFP.KILy5.1 reporter mice.
Atg5ﬂox/ﬂox 61 and C57BL/6J-Tg(Itgax-cre,-EGFP)4097Ach/J mice (JAX 00756762)
were crossed to obtain Atg5ﬂ/ﬂxItgaxCre/− mice; Atg5ﬂox/ﬂox and Atg5ﬂ/WTxIt-
gaxCre/− mice mice were used as littermate controls. All mice were on the
C57BL/6 background, used at 7–22 weeks of age, and age and sex matched
within experiments.
LCMV strains Armstrong, WE, clone 13 and Docile were propagated on L929
ﬁbroblasts, Vaccinia virus on BSC40, and MCMV on M2-10B4 cells. Mice were
infected intravenously (i.v.) with 200 f.f.u. LCMV for low dose infection or with
106 f.f.u. for high-dose infection, with 2 × 105 p.f.u. MCMV, or intraperitoneally
(i.p.) with 2 × 106 p.f.u. Vaccinia virus. Non-replicating LCMV clone 13 was
generated by exposure to UV light for 60 min at RT. When indicated, animals were
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Fig. 6 Schematic representation of virus-induced alterations in Treg cells and their impact on colitis. Virus-induced type I IFN responses transiently
impair the Treg cell compartment. The Treg pool is rapidly replenished by iTreg cells converted from a high-afﬁnity CD4+ T cell population (Vβ5+ CD4+
T cells in mice and Vβ2+ CD4+ T cells in humans) and returns to homeostasis. If this process is impaired, the lack of Treg-mediated suppression allows for
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pulsed with 1 mg BrdU (Biolegend) i.p. 24 h before sacriﬁce. Broad-spectrum
antibiotic therapy using ampicillin, vancomycin, neomycin, and metronidazol
(Sigma) was applied in drinking water as described63. To measure gut permeability,
animals were deprived of food and drink for 3 h and then fed with 15 mg 4 kDa
FITC-dextran (TdB Cons) as described38. Serum was collected and analyzed for
ﬂuorescence 4 h later by Spectramax i3 (Molecular Devices). For assessment of
colitis, organs were ﬁxed in PFA, and parafﬁn-embedded cecal sections were
visualized by hematoxylin-eosin staining (Veterinary Pathology, University of
Zurich, Switzerland). Histopathological scoring was determined as previously
described64. Brieﬂy, sections were scored for (i) submucosal edema, (ii) PMN
inﬁltration into the lamina propria, (iii) goblet cell loss, and (iv) epithelial integrity
and were given a score from 0 to 3 (0= no pathological changes; 1=mild changes;
2=moderate changes; 3= profound changes).
Human samples. Peripheral blood was collected from healthy donors (approved by
Cantonal Ethics Committee of Zurich, BASEC number 2016-01440) and IBD patients
with active (Colitis activity index > 6) or inactive (Colitis activity index < 3) disease
that were neither on anti-TNFα nor on steroid therapy (approved by Cantonal Ethics
Committee of Zurich, EK-1316) and informed consent was obtained prior to blood
collection. For T cell sequencing, T cells were sorted from peripheral blood of 6 age-
matched healthy Caucasian male donors. Furthermore, whole blood from healthy
donors and IBD patients was collected and directly analyzed by ﬂow cytometry.
Flow cytometry and T cell stimulation. Single cell suspensions from the indicated
organs were used directly for extracellular staining (45 min at 4 °C) or restimulated
ex vivo. For restimulation, isolated splenocytes were incubated for 4 h at 37 °C in
the presence of PMA and ionomycin (Sigma) or the LCMV-immunodominant
peptides gp61 and gp33 (EMC Microcollections), together with brefeldin A (Bio-
legend). Gut contents (GC) were homogenized in PBS using metal balls and a
TissueLyser II (25 Hz, 3 min; Qiagen) and sedimented for 10 min at 8000 g at 4 °C.
Sterile ﬁltered GC (0.22 μm unit, Merck Millipore) were mixed at a 1:5 vol ratio
with isolated splenocytes and incubated for 2 h at 37 °C, before brefeldin A was
added for an additional 4 h. For transcription factor staining the Foxp3 Staining
Buffer Set (Thermo Fisher) and for intracellular cytokine staining the BD Fixation/
Permeabilization Solution kits (BD Bioscience) were used according to the man-
ufacturer’s instructions.
All ﬂuorescently labeled antibodies—for murine samples: CD4 (RM4-5 or GK1.5),
CD8 (53-6.7), CXCR3 (CXCR3-173), Nrp1 (3E12), Foxp3 (FJK-16s), TCR Vβ5.1,5.2
(MR9-4), Vβ8.1,8.2 (KJ16-133.18), TCR γδ (GL3/UC7-13D5), Vβ2 (B20.6), Vβ6
(RR4-7), Vβ7 (TR310), Vβ8.3 (1B3.3), Vβ10b (B21,5), Vβ11 (RR3-15/KT11), Vβ12
(MR11-1), and Vβ13 (MR12-4), CD44 (IM7), CD62L (MEL-14), TIGIT (1G9), LAG3
(C9B7W), PD-1 (J43), CD39 (Duha59), CD73 (TY/11.8), CD85k (H1.1), BrdU
(Bu20a), IFN-γ (XMG1.2), CD5 (53-7.3), CD11c (N418), MHCII (M5/114.15.2),
CD45.1 (A20), CD90.1 (OX-7); for human samples: CD3 (OKT3), CD4 (SK3), CD8
(SK1), CD19 (HIB19), CD25 (M-A251), CD45RA (HI100), and CD127 (A019D5)—
were purchased from Biolegend, eBioscience, or BD Biosciences. For T cell
spectratyping from human PBMCs, the IOTest Beta Mark TCR Vβ Repertoire Kit
was used (Beckman Coulter). To detect live cells, the Zombie-NIR ﬁxable dye (for
murine cells) and 7-AAD (for human cells) were used. LSRFortessa or FACSCanto II
cytometers were used for cell acquisition and a FACS Aria III 5L was used for cell
sorting (all BD Bioscience; Core Facility, University of Zurich, Switzerland). Data
analysis was carried out using the Flowjo software (Treestar).
Cell sorting and adoptive cell transfers. Single cell suspensions of splenic T cells
were obtained by mechanic disruption. For obtaining high purity APCs, spleens
were additonally subjected to enzymatic digestion by collagenase D (Gibco) and
DNase I (VWR) for 45 min at 37 °C. Prior to cell sorting, cells were enriched by
magnetic cell sorting (MACS) using anti-CD4, anti-CD11c, or Pan T cell MojoSort
beads (Biolegend). Wild-type or congenically marked cells were sorted as CD8+
T cells, CD4+ T cells, CD4+Vβ5.1,5.2− T cells, CD4+Foxp3+Vβ5.1,5.2+ Treg cells,
CD4+CD25− T cells, CD4+Foxp3− T cells, or CD11c+MHCII+ APCs. For T cell
reconstitution, 1.8 × 106 CD8+ and 2 × 106 CD4+ T cells were co-injected i.v. into
Tcrbtm1MomTcrdtm1Mom recipient mice, and allowed to reconstitute for 1 or
>7 days before LCMV challenge as indicated.
Type I bioassay. 20’000 LL171 cells/well were grown in a 96 well ﬂat bottom
luciferase reading plate over night in 10% RPMI medium supplemented 1% L-
glutamine (all Gibco). On the next day, 10-fold pre-diluted test sera and respective
IFN-β standard (Biolegend) were added in RPMI medium and incubated for 24 h
at 37 °C. The cells were then lysed in 1x lysis buffer (Promega) for 10 min, followed
by the addition of luciferase substrate (Promega) via injector system. The luciferase
activity was measured on a Tecan Inﬁnite 200 Pro plate reader.
In vitro Treg cell assays. T cells were cultured in RPMI medium supplemented
with 10% heat-inactivated FCS, 50mM β-mercaptoethanol, 1 mM sodium pyruvate,
nonessential amino acids, MEM vitamins, 50 U/mL penicillin, 50 µg/mL strepto-
mycin, 2 mM glutamine (all from Gibco), and 50 µg/mL gentamicin (Sigma) and
Treg cell suppression assays were conducted as previously described30. Brieﬂy, sorted
CD4+Foxp3− conventional T cells (4 × 104/well) were co-cultured in triplicate with
the indicated CD4+CXCR3+Foxp3+ Treg subsets in the presence of soluble anti-
CD3 (1 μg/ml, BioXcell) and irradiated splenic APCs (2 × 105/well) for 48 h at 37 °C.
Cells were then pulsed with 1 μCi [3H]thymidine (PerkinElmer) for an additional
18–22 h and thymidine incorporation was assessed to determine effector T cell
proliferation. Secreted IFN-γ levels were determined in supernatants using the
LEGENDplex cytometric bead array (Biolegend). For in vitro induction of Treg cells,
sorted CD4+Foxp3− T cells and CD11c+MHCII+ APCs were cultured for 72 h at
37 °C in the presence of soluble anti-CD3 (5 ng–0.5 μg/ml, BioXcell), recombinant
human TGF-β1 (0.3 or 3 ng/ml, RayBio), recombinant mouse IL-2 (2 or 20 U/mL),
anti-IL-4 (1 μg/ml, 11B11), and anti-IFN-γ (1 μg/ml, XMG1.2; all from Biolegend).
Alternatively, T cells were stimulated with plate bound anti-CD3 (0.5 μg/ml) and
anti-CD28 (2 μg/ml), TGF-β1 (3 ng/ml), IL-2 (20 /mL), anti-IL-4 (1 μg/ml, 11B11),
and anti-IFN-γ (1 μg/ml, XMG1.2) and type I IFN (3000U/ml) where indicated.
Acquired expression of Foxp3 was subsequently assessed by ﬂow cytometry.
Foci forming assays. Viral titers in infectious inoculum and in indicated organs
were determined as described previously65. In brief, homogenized samples were
serially diluted (10-fold) onto MC57G cells seeded into 24-well plates (105/well) in
MEM supplemented with 5% FCS and 1% PSG (Corning and Gibco). Infected cells
were overlayed 4 h later with a 1:1 mix of 2% methylcellulose (Sigma) and 5% FCS/
DMEM medium (Gibco), and incubated for an additional 48 h at 37 °C. Cells were
ﬁxed with 4% PFA, permeabilized with 1% Triton X-100, and stained with rat anti-
LCMV VL-4 and peroxidase-conjugated goat anti-rat IgG (Jackson ImmunoR-
esearch). For visualization OPD (Sigma) substrate was applied for >30min at RT.
RNA-seq data and analysis. For mouse samples, CD4+ T cells were pre-puriﬁed
from splenocytes and LNs of naive or LCMV WE infected (day 14) Foxp3-GFP.KI
reporter mice using anti-CD4 beads (Miltenyi). CD4+Foxp3− conventional T cells
and CD4+Foxp3+, CD4+Foxp3+CXCR3+ or CD4+Foxp3+CXCR3− Treg cells
were sorted by ﬂow cytometry. RNA was extracted using the Qiagen RNeasy Micro
Kit and libraries were prepared and sequenced by the Functional Genomics Center
Zurich (Zurich, Switzerland). Human PBMCs were isolated by Ficoll-Paque (GE
Healthcare) densitiy centrifugation and 2000 cells were sorted as 7-AAD−CD3+
CD4+CD127−CD25high Treg cells and 7-AAD−CD3+CD4+CD127varCD25var
effector T cells from human PBMCs (see Supplementary Fig. 6a for gating strat-
egy). For RNA isolation, the Smart-Seq2 protocol was applied as described in
ref. 66. Brieﬂy, Agencourt RNAClean XP paramagnetic beads (Beckman Coulter)
were used in combination with a DynaMag-96 side skirted magnet (Thermo
Fisher). cDNA was generated with SuperScript II Reverse Transcriptase Kit
(Thermo Fisher) and ampliﬁed with HiFi HotStart PCR Mix (KAPA Biosystems).
For DNA clean-up Agencourt AMPure XP beads were used (Beckman Coulter) as
above. Nextera XT DNA sample preparation and index kits (Illumina) were used
for preparation of libraries that were sequenced by the Functional Genomics
Center Zurich (Zurich, Switzerland). RNA-Seq reads of the Treg murine samples
from this experiment were already published previously30. RNA-Seq reads were
aligned to the mouse (Ensembl_GRCm38.75) or human reference genome
(Ensembl_GRCh38) using Subread (v1.6.2) using only uniquely mapping reads67.
Both mouse and human expression levels were quantiﬁed at the gene-level using
the featureCounts function of the Rsubread package68 with NCBI Entrez IDs.
Normalized counts for the TRBV genes were quantiﬁed using the R package
edgeR69. Repertoire analysis from RNA-seq data was performed using MiXCR
software (version 3.0.3) allowing for partial alignments and performing two rounds
of subsequent contig assembly. Clonotypes were assembled using the CDR3 feature
and exported using default parameters70.
Statistical evaluation. Statistical signiﬁcance was determined using
Mann–Whitney U or one-way ANOVA with Tukey’s multiple comparison post
tests (GraphPad Prism 6). Signiﬁcance is indicated as p ≥ 0.05 (not signiﬁcant, n.s.),
p < 0.05 (*), p < 0.01 (**) or p < 0.001 (***).
Reporting summary. Further information on research design is available in
the Nature Research Reporting Summary linked to this article.
Data availability
Source data for all ﬁgures and Supplementary Figures are provided with the paper. RNA-
Seq data that support the ﬁndings of this study have been deposited at the ArrayExpress
database at EMBL-EBI (www.ebi.ac.uk/arrayexpress) and are available via the accession
numbers E-MTAB-8861 (mouse T cells) and MTAB-8819 (human T cells). Within E-
MTAB-8861, T-conventional cell sequences are reported in this study for the ﬁrst time,
while Treg sequences from the same experiment have been also described in our earlier
publication30 and shared as the dataset E-MTAB-6156.
Code availability
All code used in this study has been decribed previously. Subread (http://subread.
sourceforge.net), edgeR (https://bioconductor.org/packages/release/bioc/html/edgeR.
html), and MiXCR (https://github.com/milaboratory/mixcr/releases) are available via the
indicated links.
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